Skip to main content

Call for papers - Overcoming therapy resistance in prostate cancer

Guest Editors:
Holger Erb: Dresden University of Technology, Germany
Jacob Orme: Mayo Clinic, US

Submission Status: Open   |   Submission Deadline: 19 July 2024

BMC Cancer seeks submissions to a new Collection, focused on understanding and combating resistance mechanisms in advanced prostate cancer. We hope it can serve to highlight new research on this topic including ADT and taxane chemotherapy resistance, tumor microenvironment impacts, biomarkers, metastasis mechanisms, targeted therapies, and enhanced immunotherapies.

Meet the Guest Editors

Back to top

Holger Erb, PhD: Dresden University of Technology, Germany

Dr Holger Erb is a seasoned molecular biologist with over a decade of experience in prostate cancer (PCa) research who has successfully published multiple therapy resistance-related publications in recent years. Currently, he serves as deputy laboratory manager at “Klinik und Poliklinik für Urologie Universitätsklinikum Dresden” (Germany) and leads his research group in translational uro-oncology. Holger Erb holds a PhD in molecular pathology and finished his Venia Legendi in 2022. His expertise includes prostate cancer, androgen receptor signaling, molecular biology, and therapy resistance.

Jacob Orme, MD, PhD: Mayo Clinic, US

Jacob Orme, MD, PhD, is a genitourinary medical oncologist and translational physician scientist who works in the clinic and the laboratory to make cancer care better for his patients. Dr Orme discovered the source and consequence of soluble PD-L1 in immunotherapy-resistant cancers as well as a novel biomarker "switch" in advanced highly-resistant prostate cancers. These discoveries have led to the development of multiple new experimental therapeutics and clinical trials. Dr Orme has received awards from Mayo Clinic, the Minnesota Society of Clinical Oncology, the National Institutes of Health, and the Prostate Cancer Foundation to support his work.

About the Collection

Globally, more than 1.4 million new prostate cancer cases were diagnosed in 2020 (PMID 35252092) and Advanced Prostate Cancer (PCa) comprises approximately 1% of all deaths in the United States each year (PMID 36633525). While androgen deprivation therapy (ADT) can be effective against many prostate cancers, resistance to therapy causes most PCa deaths. Lethal prostate cancers become resistant to ADT and other therapies through a variety of cellular pathways and mechanisms. The field is making advances to overcome resistance to existing chemotherapies, hormone therapies, immunotherapies, and radiation and radioligand-based therapies. The development of new targeted therapies will further help to meet the challenge of treating therapy resistant PCa. 

BMC Cancer invites submissions to this Collection to better understand resistance mechanisms and develop new therapies for advanced prostate cancer. Topics of interest include, but are not limited to, the following:

  • Understanding resistance mechanisms against ADT and taxane chemotherapies
  • Involvement of the tumor microenvironment in ADT/chemotherapy efficacy/resistance
  • Biomarkers of resistance and treatment outcomes 
  • Mechanisms of metastasis
  • Development of targeted therapies 
  • Identification of genetic and epigenetic targets for prostate cancer
  • Overcoming the immunosuppressive tumor environment and development of effective immunotherapies in prostate cancer

Image credit: Pissanu /

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Overcoming therapy resistance in prostate cancer" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.